PrimeRFP SCOUT · Federal Contract Recompete Brief

75N93024C00017Vesivax tlr7 formula — Molecular Express, Inc

Molecular Express, Inc holds $5.6M across 3 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 1 related award in the incumbent pipeline. Competition previously drew 16 offers. Set-aside status: NONE. Recompete timing centers on the Aug 31, 2027 PoP end — agencies typically plan 12–18 months ahead.

National Institutes Of Health Niaid

Awarding office

Molecular Express, Inc

Recipient

Aug 31, 2027

PoP end

$3M

Obligated

$3M

Potential

541714

NAICS

AN12

PSC

NONE

Set-aside

16 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Molecular Express, Inc — $90

Contract facts

NONE

Contract number75N93024C00017

AgencyNational Institutes Of Health Niaid

Awarding officeNational Institutes Of Health Niaid

Awarding agencyDepartment of Health and Human Services (HHS)

Funding agencyDepartment of Health and Human Services (HHS)

IncumbentMolecular Express, Inc

CAGE337D8

UEIR1JMHFESEKD5

NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN12

Place of performanceCOMPTON CA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

Related solicitationPHS2024-1

PoP startSep 1, 2024

PoP end (current)Aug 31, 2027

Obligated$3M

Current value$3M

Potential value$3M

VESIVAX TLR7 FORMULA is a federal NONE award for National Institutes Of Health Niaid held by Molecular Express, Inc. Estimated value $3M ($3M obligated). Current period of performance ends Aug 31, 2027. Last award drew 16 bidders. Place of performance: COMPTON CA. Related solicitation PHS2024-1.

Recompete timing

Public

● Expiring in 358 days

Current PoP ends Aug 31, 2027 (358 days remaining). Agencies typically plan 12–18 months ahead — at 11.8 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Molecular Express, Inc — $5.6M obligated across 3 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$5.6M · 100% of firm total

Open full company profile →

Related awards

Same incumbent

75N93024C00018

DESIGN AND ENGINEERING OF VESIVAX HIV IMMUNOGEN FORMULATIONS

$2.0M

Aug 31, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75N93024C00017?

75N93024C00017 (Vesivax tlr7 formula) is a National Institutes Of Health Niaid award with a potential value of $3M, currently held by Molecular Express, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75N93024C00017?

National Institutes Of Health Niaid awarded 75N93024C00017 to Molecular Express, Inc (potential $3M).

Who is the incumbent on 75N93024C00017?

Molecular Express, Inc is the incumbent with $5.6M across 3 related awards in SCOUT’s public footprint. The current period of performance ends Aug 31, 2027.

When does Molecular Express, Inc’s 75N93024C00017 come up for recompete?

SCOUT tracks a period-of-performance end of Aug 31, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 75N93024C00017 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jun 26, 2026 · refreshed monthlyLatest procurement action Jul 16, 2026